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ABSTRACT
Objective IBS shows genetic predisposition, but
adequately powered gene-hunting efforts have been
scarce so far. We sought to identify true IBS genetic risk
factors by means of genome-wide association (GWA)
and independent replication studies.
Design We conducted a GWA study (GWAS) of IBS in a
general population sample of 11 326 Swedish twins. IBS
cases (N=534) and asymptomatic controls (N=4932)
were identiﬁed based on questionnaire data. Suggestive
association signals were followed-up in 3511 individuals
from six case-control cohorts. We sought genotype-gene
expression correlations through single nucleotide
polymorphism (SNP)-expression quantitative trait loci
interactions testing, and performed in silico prediction of
gene function. We compared candidate gene expression
by real-time qPCR in rectal mucosal biopsies of patients
with IBS and controls.
Results One locus at 7p22.1, which includes the genes
KDELR2 (KDEL endoplasmic reticulum protein retention
receptor 2) and GRID2IP (glutamate receptor, ionotropic,
delta 2 (Grid2) interacting protein), showed consistent
IBS risk effects in the index GWAS and all replication
cohorts and reached p=9.31×10−6 in a meta-analysis of
all datasets. Several SNPs in this region are associated
with cis effects on KDELR2 expression, and a trend for
increased mucosal KDLER2 mRNA expression was
observed in IBS cases compared with controls.
Conclusions Our results demonstrate that general
population-based studies combined with analyses of
patient cohorts provide good opportunities for gene
discovery in IBS. The 7p22.1 and other risk signals
detected in this study constitute a good starting platform
for hypothesis testing in future functional investigations.
Signiﬁcance of this study
What is already known on this subject?
▸ IBS is a functional GI disorder of high
prevalence and largely unknown aetiology and
pathophysiology.
▸ A genetic component has long been recognised
in IBS, but gene-hunting efforts have, thus far,
been scarce.
What are the new ﬁndings?
▸ We report the ﬁrst genome-wide association
study of IBS in a general population-based
sample, with follow-up in multiple case-control
cohorts.
▸ We identiﬁed a suggestive locus at 7p22.1,
with genetic risk effects replicated in all
case-control cohorts.
▸ The genes KDLER2 and GRIP2IP map to the
associated locus, and genetic variation in this
region modulates KDLER2 mRNA expression.
How might it impact on clinical practice in
the foreseeable future?
▸ Population-based cohorts with associated
genetic and epidemiological data provide
excellent opportunities to study the genetic
architecture of IBS, and its potential relevance
to disease pathophysiology.
▸ Such genetic information may inform
stratiﬁcation of patients into different risk
groups and allow for better targeted allocation
of care.
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INTRODUCTION
IBS is a functional GI disorder that manifests predominantly in
women, with symptoms including abdominal pain, bloating,
constipation (IBS-C), diarrhoea (IBS-D) or alternating constipa-
tion and diarrhoea (IBS-M, mixed type).1 IBS affects a consider-
able portion of the general population, impacting up to 10%–
15% in Westernised countries, where it consumes 0.5% of the
national healthcare budget.2 3 There is still very little under-
standing of IBS pathophysiology, and diagnosis is primarily
based on structured symptomatic information established
through expert consensus by the Rome Foundation.4 Most
patients are managed in primary care where a more pragmatic
approach to the diagnosis is used, however, reasonably well in
accordance with the Rome criteria.5
IBS is likely a multifactorial disease, where hypervigilance of
the central nervous system, mucosal immune activation, micro-
biome, prior infections and diet are all suspected to play a role.6
A heritable component has been demonstrated in epidemio-
logical studies in families and twins7 and, more recently, in a
nation-wide survey of the Swedish population where increased
risk of IBS was detected among ﬁrst, second and third degree
relatives of IBS probands.8 However, gene-hunting efforts in
IBS have thus far been rather scarce and largely limited to candi-
date gene approaches in small sample sets of cases and controls,
which resulted in that no unequivocal IBS risk gene has been
identiﬁed to date.9 Possibly, the TNFSF15 gene represents the
only exception: we originally reported that genetic variation at
the corresponding locus is associated with increased risk of IBS
and, in particular, IBS-C in Swedish and US patients,10 and this
has later been corroborated by similar ﬁndings in UK and
Canadian case-control cohorts,11 12 and a recent meta-
analysis.13
No genome-wide association study (GWAS) has been reported
for IBS thus far. This may be due to the relatively small sizes of
existing patient cohorts, and/or the difﬁculty in deﬁning a
common reliable study phenotype. Recently, we hypothesised
that alternative approaches may include the study of large
general population samples, where existing genotypical and
phenotypical information may be exploited for gene-hunting
efforts in IBS, with considerable gain in sample homogeneity
and size.9 Here we report the use of data from the Screening
Across the Lifespan Twin study (SALT)14 15 for the purpose of a
GWAS of IBS, and the replication of ﬁndings in six independent
case-control cohorts from collaborating centres in Sweden, Italy,
USA, Belgium, Germany and Greece. In total, this study
includes genotypical and phenotypical information from 14 837
individuals, and represents, by far, the largest gene-hunting
effort ever conducted in IBS.
MATERIALS AND METHODS
Study subjects and patients material
Discovery population
The SALT study includes extensive epidemiological information
for 45 750 Swedish twins, born in 1958 or earlier, who partici-
pated in telephone interviews conducted between 1996 and
2002.14 Among others, GI symptoms were recorded during the
interview using an adapted version of the Rome criteria, which
allowed individuals to be classiﬁed as patients with IBS.15 The
deﬁnition of IBS based on this survey showed high reliability
(κ=0.92) and 99% concordance with Rome II and an estimated
25% heritability in the very same population, which has been
previously reported. We elected as controls SALT individuals
who reported no bowel symptoms (negative answer to the ques-
tion ‘Ever had recurrent abdominal problems’). As of 2012,
GWAS genotyping data (see below) became available for 11 326
SALT twins, mostly dizygotic twins, and we included these in
the current study. After exclusion of individuals with reported
diagnosis of IBD (both Crohn’s disease and ulcerative colitis),
coeliac disease, peptic ulcer and GI cancer, we focused our ana-
lyses on 5466 independent singletons (534 IBS cases and 4932
asymptomatic controls). Where appropriate, individual twins
were randomly selected from concordant pairs, while IBS cases
were always preferred from discordant pairs. The demographics
of the discovery sample are reported in table 1. Informed
consent was obtained from the study participants, and the study
was approved by the Ethical Committee of the Karolinska
Institutet.
Replication cohorts
Replication of GWAS ﬁndings was sought by studying six
cohorts of Caucasian IBS cases and controls from collaborating
centres in Sweden, Belgium, Italy, Germany, Greece and the
USA. The Swedish multicentre cohort has been described in
detail in our previous studies10 11 and consists of patients with
IBS (Rome II/III criteria) recruited at secondary and tertiary care
centres throughout the country, together with asymptomatic
controls. The case-control cohorts from Leuven, Belgium, and
from the Mayo Clinic in Rochester, USA, have also been exten-
sively characterised and described in detail in previous
studies.10 11 Patients with IBS (Rome II) and asymptomatic con-
trols genotyped in Heidelberg, Germany, are from the
Outpatients Departments of the University Hospitals of South
Table 1 Demographic and clinical characteristics of the study individuals
Discovery Replication Meta-analysis Replication, individual cohorts
Sweden Belgium Germany Italy Greece USA
CTRL IBS CTRL IBS CTRL IBS CTRL IBS CTRL IBS CTRL IBS CTRL IBS CTRL IBS CTRL IBS
n 4932 534 1793 1718 6725 2252 888 520 516 544 77 179 125 211 74 80 113 184
Mean
age
58.4 57.7 42.9 44.8 50.7 51.25 47.1 43.8 40.7 44.6 35 40.8 39.7 39.9 47.9 51.6 47 47.9
M:F 52:48 31:69 42:58 17:83 49:51 21:79 55:45 19:81 25:75 18:82 36:64 17:83 29:71 25:75 14:86 0:100 34:66 9:91
IBS-M 279 279 233 0 0 2 0 42
IBS-C 765 765 136 320 93 102 62 54
IBS-D 674 674 151 224 86 107 18 88
IBS-C, constipation-predominant IBS; IBS-D, diarrhoea-predominant IBS; IBS-M, IBS mixed phenotype.
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Manchester (responsible PI Lesley Houghton), and have been
recruited through local general practices, advertisement in
regional newspapers and an existing departmental volunteer
pool of patients. The Italian case-control material derives from a
recently launched multicentre study (coordinator Giovanni
Barbara, Bologna), which includes, in this study, IBS cases
(Rome III) and asymptomatic controls enrolled at St
Orsola-Malpighi Hospital in Bologna and at the Unit of
Gastroenterology at the University of Pisa. Greek consecutive
patients with IBS (Rome III) and asymptomatic controls were
recruited at the Gastroenterology outpatients division of
Evangelismos Hospital and Aretaieion Hospital, Athens between
2008 and 2013. The demographics and clinical characteristics
of patients with IBS and controls included in the replication
stage are reported in table 1. All centres received approval from
their local and national institutional review boards, and
informed consent was obtained from all participants.
Genotyping, quality control and statistical methods
Discovery GWAS
SALT individuals were genotyped using Illumina OmniExpress
arrays, and imputation was carried out using MACH16 and the
HapMap3 reference panel. Re-imputation with 1KG data was
also performed, when searching for association with rare coding
variants at the 7p22.1 locus. Single nucleotide polymorphisms
(SNP) with genotype call rate <97% and/or a Hardy–Weinberg
equilibrium (HWE) p<10−7 were excluded, together with indi-
viduals with >3% missing genotypes. This yielded a ﬁnal
number of 1 253 036 SNPs, 534 IBS cases and 4932 controls
suitable for analysis after quality control (QC). We performed
case-control association tests using an additive logistic regression
model implemented in PLINK,17 including sex and the ﬁrst six
eigenvectors as covariates (QQ-plot and Manhattan plot are
reported in online supplementary ﬁgure S1). This resulted in
the identiﬁcation of 42 independent association signals with
common (minor allele frequency >0.01) SNPs at p<10−4 in
SALT (see online supplementary ﬁgure S1). Among these, we
selected 14 signals for follow-up based on manual inspection of
individual regional linkage disequilibrium (LD) plots and at least
one of the following: (1) presence of multiple SNP association
hits at the same locus; (2) overlap with coding genes and/or
their regulatory regions (promoters); (3) presence of coding
SNPs among the best hits.
Replication
SNPs selected for replication were genotyped in case-control
cohorts on the Sequenom MassARRAY platform with iPLEX
chemistry. Two SNPs (one lead and one ‘backup’ proxy,
r2>0.8), from each region were genotyped with average success
rates 99.77%, 99.17%, 99.90%, 99.80%, 99.83% and 99.89%,
for Sweden, Belgium, Italy, Germany, Greece and the USA,
respectively, and did not signiﬁcantly deviate from HWE
(cut-off p<10−3), while none of the 3511 individuals included
in the follow-up analyses had more than 5% missing genotypes.
The replication analysis was carried out using an additive logis-
tic regression model implemented in PLINK with sex and
country of origin as covariates.
Meta-analysis
The meta-analysis was performed in PLINK using the inverse
variance-based method, and the command –meta. This
approach weights the effect estimates (β-coefﬁcent from the dis-
covery and replication set) by their SE estimates (SE) and calcu-
lates an overall OR and p value.
Purcell’s online power calculator (http://pngu.mgh.harvard.
edu/~purcell/gpc/) has been used to estimate the number of IBS
cases and controls necessary to reach genome-wide level signiﬁ-
cance for the 7p22.1 region, based on corresponding summary
statistics from GWAS, replication and meta-analysis.
eQTL and functional prediction analyses
We used Genevar (http://www.sanger.ac.uk/resources/software/
genevar)18 to retrieve information relative to expression quanti-
tative trait loci (eQTLs) associated with genetic variation in the
region of interest (between KDELR2 and GRID2IP), and used
LocusZoom (http://csg.sph.umich.edu/locuszoom)19 to plot
these data in relation to LD between SNPs. KDELR2 and
GRID2IP gene (mRNA) expression proﬁles in different anatom-
ical tissues were obtained from interrogation of public data
accessible via the Genotype-Tissue Expression portal (GTEx;
http://www.broadinstitute.org/gtex).20 For the analysis of coex-
pression with KDELR2 we adopted a two-step strategy taking
advantage of the Genevestigator search engine (http://www.
genevestigator.com).21 This is a high-performance search engine
for gene expression, integrating thousands of manually curated
public microarray data and RNA seq experiments. A list of
genes showing coregulated expression with KDELR2 was
obtained by screening 35 000 gene expression microarray
experiments and selecting genes with a correlation coefﬁcient
r>0.6 across the Perturbations dataset. This gene list was then
used with the gene functional classiﬁcation tool DAVID 6.7
(http://david.abcc.ncifcrf.gov)22 in order to identify KDELR2-
relevant enriched biological pathways according to gene
ontology terms (GO; http://www.geneontology.org). This type
of analysis was not possible for GRID2IP, since its expression
was extremely low in all tissues tested, and no genes showed
GRID2IP coregulation under the computational constraints
applied in our protocol (r>0.06 against Perturbations in
Genevestigator).
Analysis of KDELR2 intestinal mRNA expression
Rectal mucosal biopsies from 16 patients with IBS and 12 asymp-
tomatic healthy controls were collected during ﬂexible sigmoidos-
copy and stored in RNALater at −80°C until total RNA extraction
with Qiagen RNeasy kits, including a step of genomic DNA diges-
tion with DNAse for 30 min. cDNA was prepared with qScript
cDNA SuperMix kit (Quanta Biosciences) according to the manu-
facturer’s protocol, and quantitative real-time PCR (qPCR) was per-
formed using TaqMan gene expression assays (Applied Biosystems)
for KDELR2 (Hs01061971_m1) and the house-keeping gene
β-actin (ACTB, FW: 50-ACTCCATCATGAAGTGTGA; REV: 50-
GGCAGTGATCTCCTTCTG; probe FAM-BHQ1 50-TGT
ACGCCAACACAGTGCTG) in a Roche Lightcycler 96 with auto-
mated colour compensation, using default thermocycling condi-
tions. PCRs were performed in triplicate for each gene on the same
sample, and expression values normalised for the endogenous
control ACTB. Gene expression was calculated with the comparative
ΔCt method for relative quantiﬁcation
23 and expressed as fold
changes (arbitrary units) relative to a randomly chosen reference
control sample.
RESULTS
IBS GWAS in the SALT population
We used Illumina OmniExpress genotype (750 K) data available
for 11 326 twins from the SALT study, in order to conduct a
pilot GWAS of IBS in this sample representative of the general
Swedish population. SALT IBS cases were ascertained through
the use of recorded GI symptoms from questionnaire data, and
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by using a deﬁnition previously shown to have κ=0.92 and
99% concordance with Rome II and an estimated 25% heritabil-
ity in the very same population.15 HapMap3 CEU imputation
and QC ﬁltering (see the Materials and methods section), gener-
ated genotypes suitable for association testing at a total of
1 253 036 SNP markers in 5466 independent singletons, corre-
sponding to 534 IBS cases and 4932 asymptomatic controls.
GWAS analysis of IBS risk in this sample set resulted in the iden-
tiﬁcation of several markers with p<1×10−4, which mapped to
42 independent (LD-pruned) genomic regions as reported in
online supplementary ﬁgure S1A–C. However, none of these
regions reached genome-wide signiﬁcance (p<5×10−8).
Replication in independent case-control cohorts and
meta-analysis
In order to assess whether any of the identiﬁed associated regions
can be considered a true risk locus for IBS susceptibility, we
sought for follow-up assessment in a replication study. Based on
manual inspection of association data and regional LD plots from
each of the 42 associated regions (see the Materials and methods
section), 14 signals were selected for follow-up (table 2 and see
online supplementary ﬁgure 1C) and two SNPs (1 lead, 1 proxy)
from each risk locus were genotyped in 1718 IBS cases and 1793
controls from six additional independent cohorts from centres in
Sweden, Italy, Belgium, Germany, Greece and the USA (see
online supplementary table S1 and supplementary methods).
Follow-up tests for association resulted in the replication of
GWAS results for one region on chromosome 7p22.1, where
both SNPs at the corresponding locus (rs12702514 and
rs13222291) gave rise to nominally signiﬁcant ﬁndings (table 2
and see online supplementary table S1). In particular, as shown
in ﬁgure 1 for rs12702514, risk alleles at both SNPs showed
similar genetic effects with identical direction of association in all
tested populations. The 7p22.1 signal also resulted in improved
statistical evidence of association after a meta-analysis was per-
formed combining index GWAS and replication data: Pmeta for
rs12702514=5.45×10−6; Pmeta for rs13222291=1.02×10
−5
(table 2 and see online supplementary table S1). Subtype-speciﬁc
analyses (IBS-C and IBS-D were tested) did not disclose any spe-
ciﬁc pattern of preferential association within this region (data
not shown).
Gene content and genetic risk effects at the 7p22.1 risk locus
As from the SALT GWAS analysis, the peak of association at the
7p22.1 locus maps primarily to a 100 Kb region overlapping
with two genes: the whole coding region of the KDEL receptor
2 gene (KDELR2) expressed in all human tissues (see online
supplementary ﬁgure S2A) and the last two exons of the gene
for the glutamate receptor—ionotropic—delta 2 interacting
protein (GRID2IP) expressed in the brain (see online supple-
mentary ﬁgure S2B). In order to identify biological mechanisms
potentially responsible for the observed association, we sought
to evaluate the functional relevance of genetic risk effects on
the coding (protein) properties and on gene (mRNA) expres-
sion. While further supporting the association with multiple
SNP hits in the region (see online supplementary ﬁgure S3),
retesting association at the 7p22.1 locus after reimputation with
1 KG (1000 genomes) reference data did not disclose any spe-
ciﬁc signal due to common or rare missense SNPs (not shown).
This suggested that causative links may be better sought at the
regulatory level through eQTL analyses. For this purpose, we
performed genotype-gene expression correlation analyses using
the cis-eQTL—Gene function at the online GENe Expression
VARiation platform (Genevar, http://www.sanger.ac.uk/
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resources/software/genevar), and screened TwinUK data for
SNP-eQTL interactions at the 7p22.1 locus. Remarkably, several
SNPs in this region were associated with cis effects on KDELR2
expression consistently across all tested tissues (adipose, skin
and lymphoblastoid cell lines), including the GWAS and replica-
tion markers rs12702514 and rs13222291, where risk alleles
correlated with increased KDLER2 mRNA levels (see online
supplementary table S2). Also of note, association signals from
GWAS and eQTL analyses perfectly overlapped in 7p22.1
region, providing further evidence that modulation of KDELR2
gene expression may be a potential mechanism by which genetic
variation at this locus affects IBS risk. This is summarised in
ﬁgure 2, where GWAS (HapMap3 and 1 KG) and eQTL ﬁnd-
ings for this locus are reported.
Analysis of KDELR2 expression in IBS cases and controls
While GRID2IP is only detectable in the brain, KDELR2 is ubi-
quitously found in all tissues tested, and thus allows for com-
parative analyses of its mucosal expression in the GI tract of
patients with IBS and controls. For this purpose, we performed
real-time qPCR relative quantiﬁcation of KDELR2 mRNA levels
in rectal mucosal biopsies of 16 IBS cases and 12 healthy con-
trols and detected a non-signiﬁcant trend for increased KDLER2
expression among IBS cases (ﬁgure 3).
In silico prediction of KDELR2 function
The biological function of the product of the KDELR2 gene is
not known. DNA and protein sequence homology with other
members of the KDEL receptor family, in particular KDELR1,
suggests KDELR2 may play a role in vesicle trafﬁcking and trans-
port into the endoplasmic reticulum (ER). In order to gain initial
insight into its predicted function, we adopted a strategy to iden-
tify (1) genes showing KDELR2 coregulated expression and (2)
biological processes and cellular functions associated with these
genes. We screened publicly available microarray data from
35 000 gene expression experiments using the Genevestigator
search engine (http://www.genevestigator.com) and identiﬁed 32
genes showing KDELR2 coregulated expression with correlation
coefﬁcient r>0.6 across the Perturbations dataset (see online sup-
plementary table S3). We then used this gene list to interrogate
the database of GO terms (http://www.geneontology.org) with
the functional classiﬁcation tool, DAVID 6.7 (http://david.abcc.
ncifcrf.gov), in order to identify KDELR2-relevant enriched bio-
logical pathways. Conﬁrming its putative function, this analysis
resulted in the identiﬁcation of ‘endoplasmic reticulum’ and
‘ER-Golgi intermediate compartment’ as top enriched Cellular
Components, and ‘establishment of protein localization’ and
‘protein transport’ among the biological processes (see online
supplementary table S4).
Previous IBS associations in the SALT GWAS
A number of candidate genes have been implicated in IBS and
related traits (intermediate phenotypes) in the past through ﬁnd-
ings of nominal signiﬁcance (information annotated at http://
www.bellygenes.org), and we thus also explored our SALT
GWAS data at these loci. The results are reported in table 3, and
are interesting at least for some genes in that a few association
signals of nominal signiﬁcance are observed within the same
loci. For instance, CDC42, HTR3E, IL1R1, IL4, KLB, may
Figure 1 Forest plot of the association between IBS and marker
rs12702514. Shown are the individual and cumulative ORs and 95% CI
for the samples included in the study, as indicated, together with the
sample size for each single and total cohort.GWAS, genome-wide
association study; SALT, Screening Across the Lifespan Twin study.
Figure 2 Regional plot of expression
quantitative trait loci (eQTL) and
genome-wide association study
(GWAS) p values for the chromosome
7p22.1 region. eQTL- single nucleotide
polymorphism (SNP) correlations were
sought by using Genevar (http://www.
sanger.ac.uk/resources/software/
genevar) and three datasets available
for lymphoblastoid cell lines (LCL), skin
and adipose tissue, which are shown
with different colour-coded symbols in
the ﬁgure. GWAS statistics based on
CEU HapMap3 or 1KG imputation
relative to the selected region are also
reported, with colour-coded symbols as
indicated. For best representation of
the results, −log10 (p values) are
reported on a logarithmic scale, and
the speciﬁc region of overlap
containing the strongest eQTL and
GWAS association signals is
highlighted.
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represent better candidates for future replication efforts in add-
itional studies, while we recently independently replicated the
SCN5A locus in four additional case-control cohorts.24
DISCUSSION
We reported here the ﬁrst large genome-wide effort to identify
genetic determinants of IBS risk. By adopting a two-step strat-
egy, we screened a large general population sample by means of
a GWAS, and followed-up association signals in six independent
clinical case-control cohorts from different countries. A locus
on chromosome 7p22.1 consistently showed genetic risk effects
in the same direction in all seven tested sample sets, although it
still did not reach genome-wide signiﬁcance in the meta-analysis
of combined index and replication ﬁndings. Given the risk allele
frequency (rs12702514 T=0.41) and the observed effect on IBS
risk (OR from meta-analysis=1.2; 95% CI 1.13–1.30), at least
4500 IBS cases and an equal number of asymptomatic controls
would be required to achieve 80% statistical power to detect
association at 7p22.1 with genome-wide signiﬁcant p<5×10−8.
A DNA bank of this size is currently not available in the IBS sci-
entiﬁc community, hence, the GWAS data and consistent replica-
tion across multiple cohorts reported here represent the best
evidence one can currently collect for this locus.
Two genes, namely KDLER2 and GRIP2IP, map to chromo-
some 7p22.1, and our eQTL data mining efforts suggest that
genetic variation at this locus may affect IBS risk through the
modulation of gene expression. While GRID2IP is found at
detectable levels only in the brain, we were able to provide pre-
liminary support to this evidence for KDELR2, by detecting a
trend towards higher rectal mucosal expression in IBS cases com-
pared with asymptomatic controls. Given the association signal is
also primarily overlapping with KDELR2, this makes it a candi-
date stronger than GRID2IP to play a role in IBS. The product of
the KDELR2 gene belongs to a family of receptors whose
best-characterised member is KDELR1, a widely expressed
integral membrane protein with seven transmembrane
domains.25 KDELR1 (also known as human ERD2, hERD2)
binds Lys-Asp-Leu-Glu (KDEL) and Arg-Asp-Leu-Glu (RDEL)
amino acid motifs of target proteins and mediates their retro-
grade transport to the ER.25–27 Of note, some toxins from enter-
ovirulent bacteria also contain such motifs, including the
A-fragment of cholera toxin (CTA) from Vibrio cholerae, the heat
labile toxin LT1 produced by Escherichia coli and Pseudomonas
exotoxin A, which require KDELR1 binding and ER targeting in
their intracellular signalling pathway to cause secretory diarrhoea
(CTA and LT1) or cell death (exotoxin A).28–30 KDELR2 (also
known as ELP-1) appears to have similar motif-binding proper-
ties,31 and our in silico analysis of its putative function also
strongly suggests that it may have a biological function very
similar to KDELR1. Given the emerging role of host-microbiota
interactions in IBS, it is, therefore, tempting to speculate that
genotype-driven variations in KDELR2 expression may affect IBS
predisposition through mechanisms similar to those ascribed to
KDELR1, that is, in mediating the effects of bacterial toxins in
the gut.
Although poorly characterised, GRID2IP polymorphism may
also affect IBS risk. This gene encodes delphilin, a PDZ domain-
containing protein that is expressed in ﬁber-Purkinje cell synap-
ses in the brain, where it is known to bind the ionotropic
glutamate receptor δ2 (GluRδ2)32 33 and the monocarboxylate
transporter 2 (MCT2).34 Both interactants are plausible candi-
dates for potential involvement in the central and local nervous
mechanisms that are suspected to play a pathophysiological role
in IBS. Abnormal function of glutamatergic neurotransmission
has been reported in patients with IBS,35 whereas, dietary glu-
tamate might be one of the excitotoxins contributing to IBS
symptoms exacerbation.36 MTC2 is also expressed on enteric
neurons, where it has been shown to mediate the uptake of
butyrate and other short-chain fatty acids produced in the gut
lumen by resident bacteria, with induction of neurochemical
coding plasticity and increased proportion of cholinergic
neurons, and therefore increased colonic motility.37 If delphilin
function is relevant to MCT2 also in the enteric nervous system,
then GRID2IP functional polymorphisms may impact IBS risk
by affecting host-microbiota interactions in relation to gut
motility.
Our analyses were also considered in relation to the IBS can-
didate risk genes previously reported in a number of studies
(annotated at http://www.bellygenes.org). TNFSF15, which has
been consistently replicated in IBS, only showed nominal signiﬁ-
cance in the SALT GWAS (table 3). Variation in this gene has
been associated with IBS and its subphenotypes in a series of
case-control cohorts from secondary and tertiary referral centres
from Sweden, USA, UK and Canada.10–12 While increased
immune-activation has been proposed as a mechanism to
explain the observed association of TNFSF15 risk variants with
IBS,9 it is likely that corresponding genetic effects may be
diluted and more difﬁcult to detect at the general population
level, where classiﬁcation into IBS cases and controls is solely
dependent on self-reported bowel symptoms from a question-
naire. As shown in online supplementary table S4, association
signals of nominal signiﬁcance were detected for other genes,
including CDC42, HTR3E, IL1R1, IL4, KLB and SCN5A which
eventually showed better evidence of non-spurious ﬁndings.
While IL1R1 maps within the SNP rs12712124 locus that failed
replication (table 2 and see online supplementary table S1), the
SCN5A signal was followed-up and replicated in an independent
investigation that appeared in press before the current study.24
Thus, although it is difﬁcult to weight nominally signiﬁcant
Figure 3 KDELR2 mucosal expression in IBS cases and controls.
Rectal biopsies from patients with IBS and healthy individuals were
used to measure mucosal KDELR2 mRNA expression with quantitative
real-time PCR (TaqMan), which is reported in fold changes (average
plus SEM) relative to a reference sample arbitrarily chosen among the
controls (CTRL).
6 Ek WE, et al. Gut 2014;0:1–9. doi:10.1136/gutjnl-2014-307997
Neurogastroenterology
group.bmj.com on January 8, 2015 - Published by http://gut.bmj.com/Downloaded from 
association ﬁndings against the plethora of such GWAS signals,
our results may be useful to eventually shortlist previous under-
powered associations for further replication in independent
cohorts in future studies.
IBS is a particularly complex and heterogeneous phenotype,
which hampers gene-hunting efforts and requires the use of
extremely large sample sizes. While the total discovery sample
was of such large size (N=11 326), the actual set of
GWA-studied IBS cases and asymptomatic controls was of con-
siderably reduced size (534 and 4932, respectively), hence, our
results need to be taken with caution as proof-of-principle evi-
dence, and the association with the KLDER2_GRID2IP locus
conﬁrmed in additional cohorts. Nevertheless, the results pre-
sented here underscore the validity of our two-step approach,
with discovery analyses performed in a general population
sample, and replication efforts carried out in several independ-
ent case-control cohorts from GI-clinics. Hence, population-
drawn discoveries may be achieved by increasing sample size
and minimising recruitment bias, while targeted genetic associ-
ation studies in well-phenotyped patients indispensable down-
stream to validate GWAS ﬁndings, conﬁrm their clinical
relevance, and attempt to elucidate the pathophysiology behind
genotype–phenotype relationships. In addition to the 7p22.1/
KDELR2 locus replicated in six independent cohorts, SCN5A,
the gene coding for the α-subunit of the voltage-gated sodium
channel NaV1.5, is also a good example of this principle: we
detected a nominal association signal at this locus in our GWAS,
which we were prompted to follow-up, and hence replicate in
additional case-control cohorts when rare, experimentally vali-
dated loss-of-function mutations were independently identiﬁed
in a small fraction of patients with IBS from the Mayo Clinic,
Rochester, USA.24 Such a ‘re-discovery’ of disease-associated
genes fuels conﬁdence in our general population-based GWAS
approach, and suggests that both rare and common variants con-
tribute to the genetic architecture of IBS, eventually from the
same loci, like in the case of SCN5A.
In summary, we report here the ﬁrst population-based GWAS
of IBS and suggest that similar cohorts with associated genetic
and epidemiological data may provide excellent opportunities
to study the genetic architecture of IBS and related GI symp-
toms. The risk signals detected in this study, and therefore the
potential causative role of the corresponding risk loci, can be
consolidated in additional similar studies and their
meta-analyses.
Table 3 GWAS association signals for previously reported IBS risk genes
Gene Symptom and/or intermediate phenotype Best p * SNP CDS size (bp)
n SNPs in region
Total p<0.05
ADRA2A IBS-D 0.026 rs553668 3 873 6 1
ADRA2C IBS-C 0.31 rs9714431 1 958 1 0
C11orf30 Colonic transit 0.032 rs1939467 106 521 33 4
CCKAR IBS 0.378 rs915889 9 025 10 0
CDC42 IBS-C 0.010 rs2473322 40 317 22 6
CDH1 PI-IBS 0.21 rs9925080 98 250 50 0
CNR1 IBS 0.588 rs806367 26 183 7 0
COMT IBS 0.018 rs9332348 28 236 31 2
FAAH IBS-D, IBS-A, colonic transit in IBS-D 0.086 rs324419 19 582 15 0
GNB3 IBS-D, IBS-C 0.40 rs3759347 7 183 12 0
GPBAR1 Colonic filling in IBS-D 0.0037 rs10203642 2 845 6 1
HTR2A IBS 0.023 rs17069005 65 535 81 1
HTR3A IBS-D, amygdala responses, IBS severity 0.082 rs4938063 15 238 17 0
HTR3E Female IBS-D 0.0099 rs7432211 6 817 5 3
IL10 IBS 0.080 rs2222202 4 892 14 0
IL1R1 IBS 0.00019 rs3917265† 37 099 30 11
IL23R IBS 0.094 rs7517847 93 482 58 0
IL4 IBS 0.0052 rs2243250 8 693 11 7
IL6 PI-IBS, IBS 0.13 rs2069837 4 856 17 0
IL8 IBS 0.63 rs2227543 3 211 2 0
KLB Colonic transit in IBS-D 0.020 rs11933845 44 681 31 7
NPSR1 Colonic transit, sensory ratings 0.018 rs324389 191 694 126 5
NXPH1 IBS-D 0.0016 rs1981558 319 009 238 7
ORMDL3 Colonic transit 0.36 rs7224129 6 589 8 0
PRDM1 IBS, colonic transit 0.066 rs10499050 23 620 19 0
SCN5A IBS 0.00054 rs7432532‡ 101 612 89 26
SLC6A4 IBS, IBS-C, IBS-D, colonic transit 0.043 rs8073965 41 650 21 1
TLR9 PI-IBS, IBS-D 0.45 rs187084 10 152 6 0
TNF IBS, PI-IBS 0.014 rs3093671 2 769 14 1
TNFSF15 IBS, IBS-C, IBS-D, IBS-A 0.046 rs7867918 21 494 12 1
TPH1 IBS 0.20 rs10488683 20 252 13 0
*For a region containing the coding sequence (CDS) + 2 kb each side.
†Contained in the chr:2 locus tagged by SNP rs12712124, which failed replication.
‡Replicated in independent study.24
GWAS, genome-wide association study; SNP, single nucleotide polymorphism;
IBS-M, IBS mixed phenotype; IBS-C, constipation-predominant IBS; IBS-D, diarrhoea-predominant IBS; PI-IBS, post-infectious IBS; IBS-A, abdominal pain- predominant IBS; bp, base pair;
Chr, chromosome.
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